Ipsos Healthcare adds Hidradenitis Suppurativa (HS) to Global Therapy Monitor Portfolio
Ipsos Healthcare, the global healthcare division of Ipsos, has launched the Hidradenitis Suppurativa (HS) Therapy Monitor in the EU5. The HS Monitor, part of Ipsos’ Autoimmune Real World Evidence portfolio, launched in the EU5 in Q2 of 2017, with plans to extend to other markets.